Phrixus Pharmaceuticals Inc.

Phrixus Pharmaceuticals Inc. aims to repurpose a compound that may be able to boost the blood-pumping capacity of damaged hearts. Carmeseal was originally developed in the 1950s by BASF as a surfactant called poloxamer-188. If results seen in several animal cardiovascular models can be reproduced in humans, Phrixus’ compound could become an emergency room treatment for acute decompensated heart failure.